View Financial HealthThis company is no longer activeThe company may no longer be operating, as it may be out of business. Find out why through their latest events.See Latest EventsPieris Pharmaceuticals 配当と自社株買い配当金 基準チェック /06Pieris Pharmaceuticals配当金を支払った記録がありません。主要情報n/a配当利回り-0.08%バイバック利回り総株主利回り-0.08%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesReported Earnings • Nov 15Third quarter 2024 earnings released: US$2.19 loss per share (vs US$8.70 loss in 3Q 2023)Third quarter 2024 results: US$2.19 loss per share (improved from US$8.70 loss in 3Q 2023). Net loss: US$2.89m (loss narrowed 73% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 62% per year, which means it is significantly lagging earnings.お知らせ • Nov 07Pieris Pharmaceuticals, Inc., Annual General Meeting, Dec 02, 2024Pieris Pharmaceuticals, Inc., Annual General Meeting, Dec 02, 2024.Reported Earnings • Aug 16Second quarter 2024 earnings released: US$2.76 loss per share (vs US$3.63 profit in 2Q 2023)Second quarter 2024 results: US$2.76 loss per share (down from US$3.63 profit in 2Q 2023). Net loss: US$3.59m (down 190% from profit in 2Q 2023).お知らせ • Jul 25Palvella Therapeutics, Inc. agreed to acquire Pieris Pharmaceuticals, Inc. (NasdaqCM:PIRS) in a reverse merger transaction.Palvella Therapeutics, Inc. agreed to acquire Pieris Pharmaceuticals, Inc. (NasdaqCM:PIRS) in a reverse merger transaction on July 23, 2024. The provisions for calculating the Exchange Ratio are set forth in the Merger Agreement and assume a valuation for Palvella equal to $95.0 million and a valuation for Pieris equal to $21.0 million. Under the terms of the merger agreement, Pieris will issue shares of Pieris common stock to pre-merger Palvella stockholders as merger consideration in exchange for the cancellation of shares of capital stock of Palvella, and Palvella will become a wholly-owned subsidiary of Pieris. Upon termination of the Merger Agreement under specified circumstances, Pieris may be required to pay Palvella a termination fee of $1.0 million and Palvella may be required to pay Pieris a termination fee of $2.0 million. The transactions contemplated by the merger agreement have been unanimously approved by the boards of directors of both companies. The transaction is subject to approvals by the stockholders of each company, consummation of the Concurrent Financing, the effectiveness of a registration statement to be filed with the SEC to register the shares of Pieris common stock to be issued in connection with the merger, and other customary closing conditions. TD Cowen is serving as lead placement agent and Cantor is serving as a placement agent for Palvella's planned concurrent financing. Christopher S. Miller of Troutman Pepper Hamilton Sanders LLP is serving as legal counsel to Palvella. Cooley LLP is serving as legal counsel to the placement agents. Stifel is serving as the exclusive financial advisor to Pieris and William C. Hicks, Marc D. Mantell and Scott Dunberg of Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P.C. is serving as legal counsel to Pieris. Stifel, Nicolaus & Company, Incorporated acted as fairness opinion provider to Pieris. Computershare Trust Company, National Association acted as transfer agent to Pieris.New Risk • Jul 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 27% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$50m free cash flow). Share price has been highly volatile over the past 3 months (27% average weekly change). Minor Risks Shareholders have been diluted in the past year (29% increase in shares outstanding). Market cap is less than US$100m (US$10.5m market cap).分析記事 • Jul 11The Market Doesn't Like What It Sees From Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Revenues Yet As Shares Tumble 30%Unfortunately for some shareholders, the Pieris Pharmaceuticals, Inc. ( NASDAQ:PIRS ) share price has dived 30% in the...Reported Earnings • May 17First quarter 2024 earnings released: US$3.96 loss per share (vs US$14.15 loss in 1Q 2023)First quarter 2024 results: US$3.96 loss per share (improved from US$14.15 loss in 1Q 2023). Revenue: US$53.0k (down 97% from 1Q 2023). Net loss: US$4.89m (loss narrowed 63% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings.分析記事 • Apr 21Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 27% Share Price PlungePieris Pharmaceuticals, Inc. ( NASDAQ:PIRS ) shareholders won't be pleased to see that the share price has had a very...お知らせ • Apr 21Pieris Pharmaceuticals Approves 1-for-80 Reverse Stock Split to Regain Compliance with the Minimum Bid Price RequirementPieris Pharmaceuticals, Inc. announced that its board of directors has approved a 1-for-80 reverse stock split of the Company's common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time on April 22, 2024. The Company's common stock will continue to be traded on The Nasdaq Capital Market on a split-adjusted basis beginning on April 23, 2024, under the Company's existing trading symbol ‘PIRS’. The reverse stock split is intended to regain compliance with the minimum bid price requirement of $1.00 per share of the Company's common stock for continued listing on The Nasdaq Capital Market. The new CUSIP number following the reverse stock split will be 720795202. The Company filed a Certificate of Change with the Nevada Secretary of State on April 18, 2024 to effect the reverse split.Reported Earnings • Mar 31Full year 2023 earnings released: US$0.27 loss per share (vs US$0.45 loss in FY 2022)Full year 2023 results: US$0.27 loss per share (improved from US$0.45 loss in FY 2022). Revenue: US$42.8m (up 65% from FY 2022). Net loss: US$24.5m (loss narrowed 26% from FY 2022). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings.分析記事 • Mar 19We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth CarefullyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...分析記事 • Dec 18Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Not Doing Enough For Some Investors As Its Shares Slump 27%Unfortunately for some shareholders, the Pieris Pharmaceuticals, Inc. ( NASDAQ:PIRS ) share price has dived 27% in the...Reported Earnings • Nov 17Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beatThird quarter 2023 results: US$0.11 loss per share. Revenue: US$19.5m (up 264% from 3Q 2022). Net loss: US$10.8m (loss widened 10% from 3Q 2022). Revenue is expected to decline by 81% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 16%.分析記事 • Aug 18We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth CarefullyJust because a business does not make any money, does not mean that the stock will go down. For example, although...Reported Earnings • Aug 13Second quarter 2023 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2023 results: EPS: US$0.045 (up from US$0.14 loss in 2Q 2022). Revenue: US$20.1m (up 442% from 2Q 2022). Net income: US$3.98m (up US$14.3m from 2Q 2022). Profit margin: 20% (up from net loss in 2Q 2022). Revenue exceeded analyst estimates significantly. Earnings per share (EPS) also surpassed analyst estimates. Revenue is expected to decline by 17% during the next year, while revenues in the Biotechs industry in the US are expected to grow by 15%. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 57% per year, which means it is significantly lagging earnings.お知らせ • Jul 14Pieris Pharmaceuticals, Inc. Announces Executive ChangesPieris Pharmaceuticals, Inc. announced on July 13, 2023, Ahmed Mousa, the Senior Vice President, Chief Business Officer, General Counsel & Corporate Secretary of the company, gave notice that he will resign from the company effective September 11, 2023 in order to become chief executive officer of Vicore Pharma Holding AB. Mr. Mousa is expected to serve as a strategic advisor to the Company for a transition period thereafter, subject to a mutual agreement of terms in the near future. Mr. Mousa’s resignation is not a result of any disagreement with the Company or any other entity or on any matter relating to the operations, policies (including accounting or financial policies) or practices of the company. Following Mr. Mousa’s departure, Stephen Yoder, the company’s chief executive officer and President will oversee corporate and business development at the company.New Risk • Jul 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$49m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$49m free cash flow). Share price has been highly volatile over the past 3 months (25% average weekly change). Earnings are forecast to decline by an average of 8.5% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$74m net loss in 3 years). Shareholders have been diluted in the past year (11% increase in shares outstanding). Market cap is less than US$100m (US$13.6m market cap).New Risk • Jun 22New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 25% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (25% average weekly change). Earnings are forecast to decline by an average of 8.5% per year for the foreseeable future. Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$49m). Currently unprofitable and not forecast to become profitable over next 3 years (US$74m net loss in 3 years). Shareholders have been diluted in the past year (11% increase in shares outstanding). Market cap is less than US$100m (US$21.4m market cap).お知らせ • May 22+ 1 more updatePieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International ConferencePieris Pharmaceuticals, Inc. announced the presentation of preclinical data from the Company's inhaled connective tissue growth factor (CTGF) antagonist program, PRS-220, for idiopathic pulmonary fibrosis (IPF) at the annual American Thoracic Society (ATS) International Conference being held in Washington, D.C. May 19-24, 2023. The poster will be presented on May 21, 2023, from 11:30 AM to 1:15 PM (Session A67, P1052) and demonstrates that PRS-220 achieved proof of concept in a silica-induced lung fibrosis mouse model when delivered to the lung by inhalation and outperformed a systemically administered CTGF-targeting monoclonal antibody, reinforcing the transformative potential of a local intervention in this pathway. The poster also includes preclinical data demonstrating a favorable profile of PRS-220 for inhaled delivery and CTGF targeting in the lung, including a superior lung biodistribution profile compared to a systemically administered anti-CTGF monoclonal antibody, a lung PK profile supporting once or twice daily dosing in humans, and desired aerosol performance upon nebulization to effectively target pulmonary tissue of interest. PRS-220 is an inhaled Anticalin protein targeting CTGF for the treatment of IPF and other fibrotic lung diseases. Previously reported preclinical data for PRS-220 demonstrated superior on-target potency compared to pamrevlumab, an intravenously infused CTGF antagonist in late-stage clinical development. Pieris continues to benefit from a meaningful grant from the Bavarian government, which supports early-stage development of this program.Major Estimate Revision • May 17Consensus revenue estimates fall by 31%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from US$17.4m to US$12.0m. Forecast losses increased from -US$0.64 to -US$0.705 per share. Biotechs industry in the US expected to see average net income decline 85% next year. Consensus price target of US$7.00 unchanged from last update. Share price fell 6.0% to US$0.80 over the past week.分析記事 • May 15Analysts Just Shaved Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts DramaticallyThe latest analyst coverage could presage a bad day for Pieris Pharmaceuticals, Inc. ( NASDAQ:PIRS ), with the analysts...Reported Earnings • May 10First quarter 2023 earnings released: US$0.18 loss per share (vs US$0.069 loss in 1Q 2022)First quarter 2023 results: US$0.18 loss per share (further deteriorated from US$0.069 loss in 1Q 2022). Revenue: US$1.94m (down 82% from 1Q 2022). Net loss: US$13.2m (loss widened 158% from 1Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 18% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings.お知らせ • May 05Pieris Pharmaceuticals, Inc. Announces Successful Completion of Safety Review for 10 Mg Dose of Phase 2A Trial of Elarekibep (Prs-060/Azd1402)Pieris Pharmaceuticals, Inc. announced the successful safety review of the 10 mg dry powder dose safety cohort from the ongoing multi-center, placebo-controlled phase 2a study of dry powder inhaler-formulated elarekibep (PRS-060/AZD1402). The successful review of the 10 mg dose provides additional data supporting the elarekibep safety profile and enables doses of 10 mg or less to be evaluated in future clinical trials. Elarekibep is an IL-4 receptor alpha inhibitor under development in collaboration with AstraZeneca for the treatment of moderate-to-severe asthma. Pieris previously announced the successful completion of the safety review for the 1 mg and 3 mg doses, triggering the efficacy portion of the study, which is ongoing at the 3 mg dose. Upon completion of the phase 2a study and availability of topline data, which Pieris expects to be reported by mid-2024, the Company will have a co-development option for this program with AstraZeneca. For this safety review, 13 asthma patients, controlled on standard of care (medium dose inhaled corticosteroids with long-acting beta agonists), received elarekibep twice daily over four weeks to establish the safety profile and pharmacokinetics of the dry powder formulation of elarekibep at the 10 mg dose. Following completion of enrollment and observation, AstraZeneca evaluated, compared to placebo, the incidence of adverse events, changes in laboratory markers (immuno-biomarkers, clinical chemistry, and hematology), and forced expiratory volume in one second.分析記事 • Apr 17Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 41% Share Price PlungeThe Pieris Pharmaceuticals, Inc. ( NASDAQ:PIRS ) share price has fared very poorly over the last month, falling by a...Reported Earnings • Mar 31Full year 2022 earnings released: US$0.45 loss per share (vs US$0.71 loss in FY 2021)Full year 2022 results: US$0.45 loss per share (improved from US$0.71 loss in FY 2021). Revenue: US$25.9m (down 18% from FY 2021). Net loss: US$33.3m (loss narrowed 27% from FY 2021). Products in clinical trials Phase I: 3 Phase II: 1 Revenue is expected to decline by 41% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 13%. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings.お知らせ • Jan 11Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of Cd228 X 4-1Bb Bispecific Molecule (Mabcalin Sgn-Bb228 (Prs-346)Pieris Pharmaceuticals, Inc. announced that the Company has achieved a $5 million milestone from Seagen. The milestone is based on dosing the first patient in a Seagen-sponsored phase 1 study of SGN-BB228 (PRS-346), a novel bispecific antibody-Anticalin molecule (Mabcalin™) that is designed to provide a potent costimulatory bridge between tumor-specific T cells and CD228 expressing tumor cells. The Seagen-sponsored (NCT05571839) open-label phase 1 study is evaluating the safety and tolerability of SGN-BB228 in patients with advanced melanoma and other solid tumors. Secondary endpoints in the study include pharmacokinetics and antitumor activity. This program is one of three ongoing immuno-oncology programs with Seagen and preclinical data were recently presented at the Society for Immunotherapy of Cancer's (SITC) Annual Meeting in Boston. Pieris has an opt-in option to a U.S. co-promotion for one program in the collaboration.分析記事 • Dec 31Can Pieris Pharmaceuticals (NASDAQ:PIRS) Afford To Invest In Growth?We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Price Target Changed • Nov 16Price target decreased to US$7.00Down from US$8.00, the current price target is provided by 1 analyst. New target price is 593% above last closing price of US$1.01. Stock is down 74% over the past year. The company is forecast to post a net loss per share of US$0.47 next year compared to a net loss per share of US$0.71 last year.Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. Independent Director Maya Said was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 03Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beatThird quarter 2022 results: US$0.13 loss per share (improved from US$0.24 loss in 3Q 2021). Revenue: US$5.37m (up 32% from 3Q 2021). Net loss: US$9.74m (loss narrowed 41% from 3Q 2021). Revenue is expected to decline by 17% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 15%. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 35% per year, which means it is performing significantly worse than earnings.Major Estimate Revision • Aug 11Consensus revenue estimates fall by 48%The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from US$45.7m to US$23.7m. Forecast losses increased from -US$0.41 to -US$0.47 per share. Biotechs industry in the US expected to see average net income decline 46% next year. Consensus price target down from US$8.00 to US$7.00. Share price fell 9.3% to US$1.56 over the past week.分析記事 • Aug 10Bearish: This Analyst Is Revising Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Revenue and EPS PrognosticationsThe latest analyst coverage could presage a bad day for Pieris Pharmaceuticals, Inc. ( NASDAQ:PIRS ), with the covering...Reported Earnings • Aug 05Second quarter 2022 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2022 results: US$0.14 loss per share (up from US$0.25 loss in 2Q 2021). Revenue: US$3.70m (up 13% from 2Q 2021). Net loss: US$10.3m (loss narrowed 33% from 2Q 2021). Revenue exceeded analyst estimates by 14%. Earnings per share (EPS) also surpassed analyst estimates by 22%. Over the next year, revenue is expected to shrink by 45% compared to a 46% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 30% per year, which means it is performing significantly worse than earnings.Seeking Alpha • Aug 04Pieris Pharmaceuticals GAAP EPS of -$0.14 misses by $0.03, revenue of $3.7M misses by $6.77MPieris Pharmaceuticals press release (NASDAQ:PIRS): Q2 GAAP EPS of -$0.14 misses by $0.03. Revenue of $3.7M (+12.5% Y/Y) misses by $6.77M. Cash, equivalents, and investments totaled $80.9 million for the quarter ended June 30, 2022, compared to a cash and cash equivalents balance of $117.8 million for the quarter ended December 31, 2021.. Shares +4.95% PM.Reported Earnings • May 13First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: US$0.069 loss per share. Revenue: US$11.0m (down 30% from 1Q 2021). Net loss: US$5.10m (loss widened 22% from 1Q 2021). Revenue exceeded analyst estimates by 23%. Earnings per share (EPS) also surpassed analyst estimates by 19%. Over the next year, revenue is forecast to grow 72%, compared to a 25% growth forecast for the industry in the US.Major Estimate Revision • May 12Consensus estimates of losses per share improve by 23%The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from US$45.2m to US$45.7m. EPS estimate increased from -US$0.53 per share to -US$0.41 per share. Biotechs industry in the US expected to see average net income decline 44% next year. Consensus price target of US$8.00 unchanged from last update. Share price fell 34% to US$1.67 over the past week.Board Change • Apr 27Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 11 experienced directors. No highly experienced directors. Independent Director Maya Said was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Mar 03Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2021 results: US$0.71 loss per share (down from US$0.68 loss in FY 2020). Revenue: US$31.4m (up 7.1% from FY 2020). Net loss: US$45.7m (loss widened 23% from FY 2020). Revenue exceeded analyst estimates by 23%. Earnings per share (EPS) missed analyst estimates by 19%. Over the next year, revenue is forecast to grow 125%, compared to a 71% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.Seeking Alpha • Jan 09Pieris: Early Stage Developer Of Novel Asset ClassPieris develops anticalin-based therapies. These are proteins that are smaller than most, enabling inhaled formulations and better tissue penetration. A number of big pharma are interested.分析記事 • Dec 15We're Not Very Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Reported Earnings • Nov 05Third quarter 2021 earnings released: US$0.24 loss per share (vs US$0.26 loss in 3Q 2020)The company reported a solid third quarter result with improved revenues and control over costs, although losses increased. Third quarter 2021 results: Revenue: US$4.06m (up 38% from 3Q 2020). Net loss: US$16.5m (loss widened 16% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.Board Change • Nov 03Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. No highly experienced directors. Independent Director Maya Said was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Seeking Alpha • Oct 27Progress At Pieris PharmaceuticalsToday, we revisit a promising small cap biopharma concern named Pieris Pharmaceuticals for the first time in just over two years. The company has made some progress advancing its pipeline and recently signed a potentially significant collaboration deal with Genentech. A full investment analysis follows in the paragraphs below.Reported Earnings • Aug 08Second quarter 2021 earnings released: US$0.25 loss per share (vs US$0.095 loss in 2Q 2020)The company reported a poor second quarter result with increased losses, weaker revenues and weaker control over costs. Second quarter 2021 results: Revenue: US$3.29m (down 71% from 2Q 2020). Net loss: US$15.5m (loss widened 213% from 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.Major Estimate Revision • Aug 05Consensus revenue estimates increase to US$32.5mThe consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from US$21.8m to US$32.5m. Forecast losses expected to reduce from -US$0.90 to -US$0.78 per share. Biotechs industry in the US expected to see average net income decline 13% next year. Consensus price target of US$8.50 unchanged from last update. Share price rose 9.9% to US$3.76 over the past week.分析記事 • Aug 05Analysts Just Made A Noticeable Upgrade To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) ForecastsShareholders in Pieris Pharmaceuticals, Inc. ( NASDAQ:PIRS ) may be thrilled to learn that the analysts have just...Price Target Changed • Jul 06Price target increased to US$8.50Up from US$7.50, the current price target is an average from 3 analysts. New target price is 132% above last closing price of US$3.66. Stock is up 13% over the past year.お知らせ • Jun 28Pieris Pharmaceuticals, Inc.(NasdaqCM:PIRS) dropped from Russell 3000E Growth IndexPieris Pharmaceuticals, Inc.(NasdaqCM:PIRS) dropped from Russell 3000E Growth Index分析記事 • Jun 19We Think Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) CEO Compensation Package Needs To Be Put Under A MicroscopeShareholders will probably not be too impressed with the underwhelming results at Pieris Pharmaceuticals, Inc...Major Estimate Revision • May 24Consensus revenue estimates fall to US$22.0mThe consensus outlook for revenues in 2021 has deteriorated. 2021 revenue forecast decreased from US$29.7m to US$22.0m. Forecast losses increased from -US$0.69 to -US$0.90 per share. Biotechs industry in the US expected to see average net income decline 7.2% next year. Consensus price target down from US$9.00 to US$7.50. Share price was steady at US$1.93 over the past week.分析記事 • May 22Need To Know: Analysts Just Made A Substantial Cut To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) EstimatesMarket forces rained on the parade of Pieris Pharmaceuticals, Inc. ( NASDAQ:PIRS ) shareholders today, when the...Price Target Changed • May 20Price target decreased to US$7.50Down from US$9.00, the current price target is an average from 2 analysts. New target price is 308% above last closing price of US$1.84. Stock is down 40% over the past year.分析記事 • May 19Will Pieris Pharmaceuticals (NASDAQ:PIRS) Spend Its Cash Wisely?We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Reported Earnings • May 18First quarter 2021 earnings released: US$0.074 loss per share (vs US$0.065 loss in 1Q 2020)The company reported a solid first quarter result with improved revenues and control over costs, although losses increased. First quarter 2021 results: Revenue: US$15.6m (up 18% from 1Q 2020). Net loss: US$4.17m (loss widened 16% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has fallen by 31% per year, which means it is performing significantly worse than earnings.Reported Earnings • Apr 01Full year 2020 earnings released: US$0.68 loss per share (vs US$0.56 loss in FY 2019)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: US$29.3m (down 37% from FY 2019). Net loss: US$37.2m (loss widened 32% from FY 2019). Products in clinical trials Phase I: 1 Phase II: 1 Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has fallen by 27% per year, which means it is performing significantly worse than earnings.分析記事 • Apr 01Analysts Are Betting On Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) With A Big Upgrade This WeekCelebrations may be in order for Pieris Pharmaceuticals, Inc. ( NASDAQ:PIRS ) shareholders, with the analysts...Is New 90 Day High Low • Mar 09New 90-day low: US$2.41The company is down 11% from its price of US$2.70 on 08 December 2020. The American market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$1.60 per share.分析記事 • Mar 08Here's What Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Shareholder Ownership Structure Looks LikeEvery investor in Pieris Pharmaceuticals, Inc. ( NASDAQ:PIRS ) should be aware of the most powerful shareholder groups...Is New 90 Day High Low • Feb 11New 90-day high: US$3.19The company is up 20% from its price of US$2.65 on 12 November 2020. The American market is up 16% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Biotechs industry, which is up 22% over the same period.分析記事 • Feb 01We're Keeping An Eye On Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Price Target Changed • Jan 30Price target raised to US$9.00Up from US$8.00, the current price target is an average from 4 analysts. The new target price is 254% above the current share price of US$2.54. As of last close, the stock is down 31% over the past year.分析記事 • Dec 28How Much Did Pieris Pharmaceuticals'(NASDAQ:PIRS) Shareholders Earn From Share Price Movements Over The Last Three Years?While it may not be enough for some shareholders, we think it is good to see the Pieris Pharmaceuticals, Inc...Is New 90 Day High Low • Dec 16New 90-day high: US$3.13The company is up 9.0% from its price of US$2.88 on 16 September 2020. The American market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 17% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.分析記事 • Dec 02How Does Pieris Pharmaceuticals' (NASDAQ:PIRS) CEO Salary Compare to Peers?Steve Yoder has been the CEO of Pieris Pharmaceuticals, Inc. ( NASDAQ:PIRS ) since 2014, and this article will examine...Major Estimate Revision • Nov 11Analysts lower revenue estimates to US$30.5mThe 2020 consensus revenue estimate decreased from US$42.0m. Earnings per share (EPS) also decreased, with analysts lowering their estimates from -US$0.48 to -US$0.64 for the same period. The Biotechs industry in the US is expected to see an average net income growth of 6.6% next year. The consensus price target was lowered from US$8.00 to US$7.67. Share price is up 13% to US$2.82 over the past week.Reported Earnings • Nov 07Third quarter 2020 earnings released: US$0.26 loss per shareThe company reported a poor third quarter result with increased losses and weaker revenues and control over expenses. Third quarter 2020 results: Revenue: US$2.94m (down 81% from 3Q 2019). Net loss: US$14.3m (loss widened 451% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 22% per year, which means it is performing significantly worse than earnings.Analyst Estimate Surprise Post Earnings • Nov 07Earnings beat expectations, revenue disappointsRevenue missed analyst estimates by 80%. Earnings per share (EPS) exceeded analyst estimates by 111%. Over the next year, revenue is expected to shrink by 32% compared to a 309% growth forecast for the Biotechs industry in the US.Is New 90 Day High Low • Sep 22New 90-day low: US$2.33The company is down 28% from its price of US$3.22 on 24 June 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.決済の安定と成長配当データの取得安定した配当: PIRSの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: PIRSの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Pieris Pharmaceuticals 配当利回り対市場PIRS 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (PIRS)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Biotechs)2.4%アナリスト予想 (PIRS) (最長3年)n/a注目すべき配当: PIRSは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: PIRSは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: PIRSの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: PIRSが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/12/16 12:28終値2024/12/13 00:00収益2024/09/30年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Pieris Pharmaceuticals, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10 アナリスト機関null nullBairdMichael KingCitizens JMP Securities, LLCJoseph PantginisH.C. Wainwright & Co.7 その他のアナリストを表示
Reported Earnings • Nov 15Third quarter 2024 earnings released: US$2.19 loss per share (vs US$8.70 loss in 3Q 2023)Third quarter 2024 results: US$2.19 loss per share (improved from US$8.70 loss in 3Q 2023). Net loss: US$2.89m (loss narrowed 73% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 62% per year, which means it is significantly lagging earnings.
お知らせ • Nov 07Pieris Pharmaceuticals, Inc., Annual General Meeting, Dec 02, 2024Pieris Pharmaceuticals, Inc., Annual General Meeting, Dec 02, 2024.
Reported Earnings • Aug 16Second quarter 2024 earnings released: US$2.76 loss per share (vs US$3.63 profit in 2Q 2023)Second quarter 2024 results: US$2.76 loss per share (down from US$3.63 profit in 2Q 2023). Net loss: US$3.59m (down 190% from profit in 2Q 2023).
お知らせ • Jul 25Palvella Therapeutics, Inc. agreed to acquire Pieris Pharmaceuticals, Inc. (NasdaqCM:PIRS) in a reverse merger transaction.Palvella Therapeutics, Inc. agreed to acquire Pieris Pharmaceuticals, Inc. (NasdaqCM:PIRS) in a reverse merger transaction on July 23, 2024. The provisions for calculating the Exchange Ratio are set forth in the Merger Agreement and assume a valuation for Palvella equal to $95.0 million and a valuation for Pieris equal to $21.0 million. Under the terms of the merger agreement, Pieris will issue shares of Pieris common stock to pre-merger Palvella stockholders as merger consideration in exchange for the cancellation of shares of capital stock of Palvella, and Palvella will become a wholly-owned subsidiary of Pieris. Upon termination of the Merger Agreement under specified circumstances, Pieris may be required to pay Palvella a termination fee of $1.0 million and Palvella may be required to pay Pieris a termination fee of $2.0 million. The transactions contemplated by the merger agreement have been unanimously approved by the boards of directors of both companies. The transaction is subject to approvals by the stockholders of each company, consummation of the Concurrent Financing, the effectiveness of a registration statement to be filed with the SEC to register the shares of Pieris common stock to be issued in connection with the merger, and other customary closing conditions. TD Cowen is serving as lead placement agent and Cantor is serving as a placement agent for Palvella's planned concurrent financing. Christopher S. Miller of Troutman Pepper Hamilton Sanders LLP is serving as legal counsel to Palvella. Cooley LLP is serving as legal counsel to the placement agents. Stifel is serving as the exclusive financial advisor to Pieris and William C. Hicks, Marc D. Mantell and Scott Dunberg of Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P.C. is serving as legal counsel to Pieris. Stifel, Nicolaus & Company, Incorporated acted as fairness opinion provider to Pieris. Computershare Trust Company, National Association acted as transfer agent to Pieris.
New Risk • Jul 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 27% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$50m free cash flow). Share price has been highly volatile over the past 3 months (27% average weekly change). Minor Risks Shareholders have been diluted in the past year (29% increase in shares outstanding). Market cap is less than US$100m (US$10.5m market cap).
分析記事 • Jul 11The Market Doesn't Like What It Sees From Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Revenues Yet As Shares Tumble 30%Unfortunately for some shareholders, the Pieris Pharmaceuticals, Inc. ( NASDAQ:PIRS ) share price has dived 30% in the...
Reported Earnings • May 17First quarter 2024 earnings released: US$3.96 loss per share (vs US$14.15 loss in 1Q 2023)First quarter 2024 results: US$3.96 loss per share (improved from US$14.15 loss in 1Q 2023). Revenue: US$53.0k (down 97% from 1Q 2023). Net loss: US$4.89m (loss narrowed 63% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings.
分析記事 • Apr 21Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 27% Share Price PlungePieris Pharmaceuticals, Inc. ( NASDAQ:PIRS ) shareholders won't be pleased to see that the share price has had a very...
お知らせ • Apr 21Pieris Pharmaceuticals Approves 1-for-80 Reverse Stock Split to Regain Compliance with the Minimum Bid Price RequirementPieris Pharmaceuticals, Inc. announced that its board of directors has approved a 1-for-80 reverse stock split of the Company's common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time on April 22, 2024. The Company's common stock will continue to be traded on The Nasdaq Capital Market on a split-adjusted basis beginning on April 23, 2024, under the Company's existing trading symbol ‘PIRS’. The reverse stock split is intended to regain compliance with the minimum bid price requirement of $1.00 per share of the Company's common stock for continued listing on The Nasdaq Capital Market. The new CUSIP number following the reverse stock split will be 720795202. The Company filed a Certificate of Change with the Nevada Secretary of State on April 18, 2024 to effect the reverse split.
Reported Earnings • Mar 31Full year 2023 earnings released: US$0.27 loss per share (vs US$0.45 loss in FY 2022)Full year 2023 results: US$0.27 loss per share (improved from US$0.45 loss in FY 2022). Revenue: US$42.8m (up 65% from FY 2022). Net loss: US$24.5m (loss narrowed 26% from FY 2022). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings.
分析記事 • Mar 19We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth CarefullyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
分析記事 • Dec 18Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Not Doing Enough For Some Investors As Its Shares Slump 27%Unfortunately for some shareholders, the Pieris Pharmaceuticals, Inc. ( NASDAQ:PIRS ) share price has dived 27% in the...
Reported Earnings • Nov 17Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beatThird quarter 2023 results: US$0.11 loss per share. Revenue: US$19.5m (up 264% from 3Q 2022). Net loss: US$10.8m (loss widened 10% from 3Q 2022). Revenue is expected to decline by 81% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 16%.
分析記事 • Aug 18We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth CarefullyJust because a business does not make any money, does not mean that the stock will go down. For example, although...
Reported Earnings • Aug 13Second quarter 2023 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2023 results: EPS: US$0.045 (up from US$0.14 loss in 2Q 2022). Revenue: US$20.1m (up 442% from 2Q 2022). Net income: US$3.98m (up US$14.3m from 2Q 2022). Profit margin: 20% (up from net loss in 2Q 2022). Revenue exceeded analyst estimates significantly. Earnings per share (EPS) also surpassed analyst estimates. Revenue is expected to decline by 17% during the next year, while revenues in the Biotechs industry in the US are expected to grow by 15%. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 57% per year, which means it is significantly lagging earnings.
お知らせ • Jul 14Pieris Pharmaceuticals, Inc. Announces Executive ChangesPieris Pharmaceuticals, Inc. announced on July 13, 2023, Ahmed Mousa, the Senior Vice President, Chief Business Officer, General Counsel & Corporate Secretary of the company, gave notice that he will resign from the company effective September 11, 2023 in order to become chief executive officer of Vicore Pharma Holding AB. Mr. Mousa is expected to serve as a strategic advisor to the Company for a transition period thereafter, subject to a mutual agreement of terms in the near future. Mr. Mousa’s resignation is not a result of any disagreement with the Company or any other entity or on any matter relating to the operations, policies (including accounting or financial policies) or practices of the company. Following Mr. Mousa’s departure, Stephen Yoder, the company’s chief executive officer and President will oversee corporate and business development at the company.
New Risk • Jul 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$49m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$49m free cash flow). Share price has been highly volatile over the past 3 months (25% average weekly change). Earnings are forecast to decline by an average of 8.5% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$74m net loss in 3 years). Shareholders have been diluted in the past year (11% increase in shares outstanding). Market cap is less than US$100m (US$13.6m market cap).
New Risk • Jun 22New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 25% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (25% average weekly change). Earnings are forecast to decline by an average of 8.5% per year for the foreseeable future. Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$49m). Currently unprofitable and not forecast to become profitable over next 3 years (US$74m net loss in 3 years). Shareholders have been diluted in the past year (11% increase in shares outstanding). Market cap is less than US$100m (US$21.4m market cap).
お知らせ • May 22+ 1 more updatePieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International ConferencePieris Pharmaceuticals, Inc. announced the presentation of preclinical data from the Company's inhaled connective tissue growth factor (CTGF) antagonist program, PRS-220, for idiopathic pulmonary fibrosis (IPF) at the annual American Thoracic Society (ATS) International Conference being held in Washington, D.C. May 19-24, 2023. The poster will be presented on May 21, 2023, from 11:30 AM to 1:15 PM (Session A67, P1052) and demonstrates that PRS-220 achieved proof of concept in a silica-induced lung fibrosis mouse model when delivered to the lung by inhalation and outperformed a systemically administered CTGF-targeting monoclonal antibody, reinforcing the transformative potential of a local intervention in this pathway. The poster also includes preclinical data demonstrating a favorable profile of PRS-220 for inhaled delivery and CTGF targeting in the lung, including a superior lung biodistribution profile compared to a systemically administered anti-CTGF monoclonal antibody, a lung PK profile supporting once or twice daily dosing in humans, and desired aerosol performance upon nebulization to effectively target pulmonary tissue of interest. PRS-220 is an inhaled Anticalin protein targeting CTGF for the treatment of IPF and other fibrotic lung diseases. Previously reported preclinical data for PRS-220 demonstrated superior on-target potency compared to pamrevlumab, an intravenously infused CTGF antagonist in late-stage clinical development. Pieris continues to benefit from a meaningful grant from the Bavarian government, which supports early-stage development of this program.
Major Estimate Revision • May 17Consensus revenue estimates fall by 31%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from US$17.4m to US$12.0m. Forecast losses increased from -US$0.64 to -US$0.705 per share. Biotechs industry in the US expected to see average net income decline 85% next year. Consensus price target of US$7.00 unchanged from last update. Share price fell 6.0% to US$0.80 over the past week.
分析記事 • May 15Analysts Just Shaved Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts DramaticallyThe latest analyst coverage could presage a bad day for Pieris Pharmaceuticals, Inc. ( NASDAQ:PIRS ), with the analysts...
Reported Earnings • May 10First quarter 2023 earnings released: US$0.18 loss per share (vs US$0.069 loss in 1Q 2022)First quarter 2023 results: US$0.18 loss per share (further deteriorated from US$0.069 loss in 1Q 2022). Revenue: US$1.94m (down 82% from 1Q 2022). Net loss: US$13.2m (loss widened 158% from 1Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 18% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings.
お知らせ • May 05Pieris Pharmaceuticals, Inc. Announces Successful Completion of Safety Review for 10 Mg Dose of Phase 2A Trial of Elarekibep (Prs-060/Azd1402)Pieris Pharmaceuticals, Inc. announced the successful safety review of the 10 mg dry powder dose safety cohort from the ongoing multi-center, placebo-controlled phase 2a study of dry powder inhaler-formulated elarekibep (PRS-060/AZD1402). The successful review of the 10 mg dose provides additional data supporting the elarekibep safety profile and enables doses of 10 mg or less to be evaluated in future clinical trials. Elarekibep is an IL-4 receptor alpha inhibitor under development in collaboration with AstraZeneca for the treatment of moderate-to-severe asthma. Pieris previously announced the successful completion of the safety review for the 1 mg and 3 mg doses, triggering the efficacy portion of the study, which is ongoing at the 3 mg dose. Upon completion of the phase 2a study and availability of topline data, which Pieris expects to be reported by mid-2024, the Company will have a co-development option for this program with AstraZeneca. For this safety review, 13 asthma patients, controlled on standard of care (medium dose inhaled corticosteroids with long-acting beta agonists), received elarekibep twice daily over four weeks to establish the safety profile and pharmacokinetics of the dry powder formulation of elarekibep at the 10 mg dose. Following completion of enrollment and observation, AstraZeneca evaluated, compared to placebo, the incidence of adverse events, changes in laboratory markers (immuno-biomarkers, clinical chemistry, and hematology), and forced expiratory volume in one second.
分析記事 • Apr 17Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 41% Share Price PlungeThe Pieris Pharmaceuticals, Inc. ( NASDAQ:PIRS ) share price has fared very poorly over the last month, falling by a...
Reported Earnings • Mar 31Full year 2022 earnings released: US$0.45 loss per share (vs US$0.71 loss in FY 2021)Full year 2022 results: US$0.45 loss per share (improved from US$0.71 loss in FY 2021). Revenue: US$25.9m (down 18% from FY 2021). Net loss: US$33.3m (loss narrowed 27% from FY 2021). Products in clinical trials Phase I: 3 Phase II: 1 Revenue is expected to decline by 41% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 13%. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings.
お知らせ • Jan 11Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of Cd228 X 4-1Bb Bispecific Molecule (Mabcalin Sgn-Bb228 (Prs-346)Pieris Pharmaceuticals, Inc. announced that the Company has achieved a $5 million milestone from Seagen. The milestone is based on dosing the first patient in a Seagen-sponsored phase 1 study of SGN-BB228 (PRS-346), a novel bispecific antibody-Anticalin molecule (Mabcalin™) that is designed to provide a potent costimulatory bridge between tumor-specific T cells and CD228 expressing tumor cells. The Seagen-sponsored (NCT05571839) open-label phase 1 study is evaluating the safety and tolerability of SGN-BB228 in patients with advanced melanoma and other solid tumors. Secondary endpoints in the study include pharmacokinetics and antitumor activity. This program is one of three ongoing immuno-oncology programs with Seagen and preclinical data were recently presented at the Society for Immunotherapy of Cancer's (SITC) Annual Meeting in Boston. Pieris has an opt-in option to a U.S. co-promotion for one program in the collaboration.
分析記事 • Dec 31Can Pieris Pharmaceuticals (NASDAQ:PIRS) Afford To Invest In Growth?We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Price Target Changed • Nov 16Price target decreased to US$7.00Down from US$8.00, the current price target is provided by 1 analyst. New target price is 593% above last closing price of US$1.01. Stock is down 74% over the past year. The company is forecast to post a net loss per share of US$0.47 next year compared to a net loss per share of US$0.71 last year.
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. Independent Director Maya Said was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 03Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beatThird quarter 2022 results: US$0.13 loss per share (improved from US$0.24 loss in 3Q 2021). Revenue: US$5.37m (up 32% from 3Q 2021). Net loss: US$9.74m (loss narrowed 41% from 3Q 2021). Revenue is expected to decline by 17% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 15%. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 35% per year, which means it is performing significantly worse than earnings.
Major Estimate Revision • Aug 11Consensus revenue estimates fall by 48%The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from US$45.7m to US$23.7m. Forecast losses increased from -US$0.41 to -US$0.47 per share. Biotechs industry in the US expected to see average net income decline 46% next year. Consensus price target down from US$8.00 to US$7.00. Share price fell 9.3% to US$1.56 over the past week.
分析記事 • Aug 10Bearish: This Analyst Is Revising Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Revenue and EPS PrognosticationsThe latest analyst coverage could presage a bad day for Pieris Pharmaceuticals, Inc. ( NASDAQ:PIRS ), with the covering...
Reported Earnings • Aug 05Second quarter 2022 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2022 results: US$0.14 loss per share (up from US$0.25 loss in 2Q 2021). Revenue: US$3.70m (up 13% from 2Q 2021). Net loss: US$10.3m (loss narrowed 33% from 2Q 2021). Revenue exceeded analyst estimates by 14%. Earnings per share (EPS) also surpassed analyst estimates by 22%. Over the next year, revenue is expected to shrink by 45% compared to a 46% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 30% per year, which means it is performing significantly worse than earnings.
Seeking Alpha • Aug 04Pieris Pharmaceuticals GAAP EPS of -$0.14 misses by $0.03, revenue of $3.7M misses by $6.77MPieris Pharmaceuticals press release (NASDAQ:PIRS): Q2 GAAP EPS of -$0.14 misses by $0.03. Revenue of $3.7M (+12.5% Y/Y) misses by $6.77M. Cash, equivalents, and investments totaled $80.9 million for the quarter ended June 30, 2022, compared to a cash and cash equivalents balance of $117.8 million for the quarter ended December 31, 2021.. Shares +4.95% PM.
Reported Earnings • May 13First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: US$0.069 loss per share. Revenue: US$11.0m (down 30% from 1Q 2021). Net loss: US$5.10m (loss widened 22% from 1Q 2021). Revenue exceeded analyst estimates by 23%. Earnings per share (EPS) also surpassed analyst estimates by 19%. Over the next year, revenue is forecast to grow 72%, compared to a 25% growth forecast for the industry in the US.
Major Estimate Revision • May 12Consensus estimates of losses per share improve by 23%The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from US$45.2m to US$45.7m. EPS estimate increased from -US$0.53 per share to -US$0.41 per share. Biotechs industry in the US expected to see average net income decline 44% next year. Consensus price target of US$8.00 unchanged from last update. Share price fell 34% to US$1.67 over the past week.
Board Change • Apr 27Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 11 experienced directors. No highly experienced directors. Independent Director Maya Said was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Mar 03Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2021 results: US$0.71 loss per share (down from US$0.68 loss in FY 2020). Revenue: US$31.4m (up 7.1% from FY 2020). Net loss: US$45.7m (loss widened 23% from FY 2020). Revenue exceeded analyst estimates by 23%. Earnings per share (EPS) missed analyst estimates by 19%. Over the next year, revenue is forecast to grow 125%, compared to a 71% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.
Seeking Alpha • Jan 09Pieris: Early Stage Developer Of Novel Asset ClassPieris develops anticalin-based therapies. These are proteins that are smaller than most, enabling inhaled formulations and better tissue penetration. A number of big pharma are interested.
分析記事 • Dec 15We're Not Very Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Reported Earnings • Nov 05Third quarter 2021 earnings released: US$0.24 loss per share (vs US$0.26 loss in 3Q 2020)The company reported a solid third quarter result with improved revenues and control over costs, although losses increased. Third quarter 2021 results: Revenue: US$4.06m (up 38% from 3Q 2020). Net loss: US$16.5m (loss widened 16% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.
Board Change • Nov 03Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. No highly experienced directors. Independent Director Maya Said was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Seeking Alpha • Oct 27Progress At Pieris PharmaceuticalsToday, we revisit a promising small cap biopharma concern named Pieris Pharmaceuticals for the first time in just over two years. The company has made some progress advancing its pipeline and recently signed a potentially significant collaboration deal with Genentech. A full investment analysis follows in the paragraphs below.
Reported Earnings • Aug 08Second quarter 2021 earnings released: US$0.25 loss per share (vs US$0.095 loss in 2Q 2020)The company reported a poor second quarter result with increased losses, weaker revenues and weaker control over costs. Second quarter 2021 results: Revenue: US$3.29m (down 71% from 2Q 2020). Net loss: US$15.5m (loss widened 213% from 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.
Major Estimate Revision • Aug 05Consensus revenue estimates increase to US$32.5mThe consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from US$21.8m to US$32.5m. Forecast losses expected to reduce from -US$0.90 to -US$0.78 per share. Biotechs industry in the US expected to see average net income decline 13% next year. Consensus price target of US$8.50 unchanged from last update. Share price rose 9.9% to US$3.76 over the past week.
分析記事 • Aug 05Analysts Just Made A Noticeable Upgrade To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) ForecastsShareholders in Pieris Pharmaceuticals, Inc. ( NASDAQ:PIRS ) may be thrilled to learn that the analysts have just...
Price Target Changed • Jul 06Price target increased to US$8.50Up from US$7.50, the current price target is an average from 3 analysts. New target price is 132% above last closing price of US$3.66. Stock is up 13% over the past year.
お知らせ • Jun 28Pieris Pharmaceuticals, Inc.(NasdaqCM:PIRS) dropped from Russell 3000E Growth IndexPieris Pharmaceuticals, Inc.(NasdaqCM:PIRS) dropped from Russell 3000E Growth Index
分析記事 • Jun 19We Think Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) CEO Compensation Package Needs To Be Put Under A MicroscopeShareholders will probably not be too impressed with the underwhelming results at Pieris Pharmaceuticals, Inc...
Major Estimate Revision • May 24Consensus revenue estimates fall to US$22.0mThe consensus outlook for revenues in 2021 has deteriorated. 2021 revenue forecast decreased from US$29.7m to US$22.0m. Forecast losses increased from -US$0.69 to -US$0.90 per share. Biotechs industry in the US expected to see average net income decline 7.2% next year. Consensus price target down from US$9.00 to US$7.50. Share price was steady at US$1.93 over the past week.
分析記事 • May 22Need To Know: Analysts Just Made A Substantial Cut To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) EstimatesMarket forces rained on the parade of Pieris Pharmaceuticals, Inc. ( NASDAQ:PIRS ) shareholders today, when the...
Price Target Changed • May 20Price target decreased to US$7.50Down from US$9.00, the current price target is an average from 2 analysts. New target price is 308% above last closing price of US$1.84. Stock is down 40% over the past year.
分析記事 • May 19Will Pieris Pharmaceuticals (NASDAQ:PIRS) Spend Its Cash Wisely?We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Reported Earnings • May 18First quarter 2021 earnings released: US$0.074 loss per share (vs US$0.065 loss in 1Q 2020)The company reported a solid first quarter result with improved revenues and control over costs, although losses increased. First quarter 2021 results: Revenue: US$15.6m (up 18% from 1Q 2020). Net loss: US$4.17m (loss widened 16% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has fallen by 31% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Apr 01Full year 2020 earnings released: US$0.68 loss per share (vs US$0.56 loss in FY 2019)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: US$29.3m (down 37% from FY 2019). Net loss: US$37.2m (loss widened 32% from FY 2019). Products in clinical trials Phase I: 1 Phase II: 1 Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has fallen by 27% per year, which means it is performing significantly worse than earnings.
分析記事 • Apr 01Analysts Are Betting On Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) With A Big Upgrade This WeekCelebrations may be in order for Pieris Pharmaceuticals, Inc. ( NASDAQ:PIRS ) shareholders, with the analysts...
Is New 90 Day High Low • Mar 09New 90-day low: US$2.41The company is down 11% from its price of US$2.70 on 08 December 2020. The American market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$1.60 per share.
分析記事 • Mar 08Here's What Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Shareholder Ownership Structure Looks LikeEvery investor in Pieris Pharmaceuticals, Inc. ( NASDAQ:PIRS ) should be aware of the most powerful shareholder groups...
Is New 90 Day High Low • Feb 11New 90-day high: US$3.19The company is up 20% from its price of US$2.65 on 12 November 2020. The American market is up 16% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Biotechs industry, which is up 22% over the same period.
分析記事 • Feb 01We're Keeping An Eye On Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Price Target Changed • Jan 30Price target raised to US$9.00Up from US$8.00, the current price target is an average from 4 analysts. The new target price is 254% above the current share price of US$2.54. As of last close, the stock is down 31% over the past year.
分析記事 • Dec 28How Much Did Pieris Pharmaceuticals'(NASDAQ:PIRS) Shareholders Earn From Share Price Movements Over The Last Three Years?While it may not be enough for some shareholders, we think it is good to see the Pieris Pharmaceuticals, Inc...
Is New 90 Day High Low • Dec 16New 90-day high: US$3.13The company is up 9.0% from its price of US$2.88 on 16 September 2020. The American market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 17% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
分析記事 • Dec 02How Does Pieris Pharmaceuticals' (NASDAQ:PIRS) CEO Salary Compare to Peers?Steve Yoder has been the CEO of Pieris Pharmaceuticals, Inc. ( NASDAQ:PIRS ) since 2014, and this article will examine...
Major Estimate Revision • Nov 11Analysts lower revenue estimates to US$30.5mThe 2020 consensus revenue estimate decreased from US$42.0m. Earnings per share (EPS) also decreased, with analysts lowering their estimates from -US$0.48 to -US$0.64 for the same period. The Biotechs industry in the US is expected to see an average net income growth of 6.6% next year. The consensus price target was lowered from US$8.00 to US$7.67. Share price is up 13% to US$2.82 over the past week.
Reported Earnings • Nov 07Third quarter 2020 earnings released: US$0.26 loss per shareThe company reported a poor third quarter result with increased losses and weaker revenues and control over expenses. Third quarter 2020 results: Revenue: US$2.94m (down 81% from 3Q 2019). Net loss: US$14.3m (loss widened 451% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 22% per year, which means it is performing significantly worse than earnings.
Analyst Estimate Surprise Post Earnings • Nov 07Earnings beat expectations, revenue disappointsRevenue missed analyst estimates by 80%. Earnings per share (EPS) exceeded analyst estimates by 111%. Over the next year, revenue is expected to shrink by 32% compared to a 309% growth forecast for the Biotechs industry in the US.
Is New 90 Day High Low • Sep 22New 90-day low: US$2.33The company is down 28% from its price of US$3.22 on 24 June 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.